03791cam a2200829 a 4500 ocn811850420 OCoLC 20171113131232.0 m o d cr ||||||||||| 121002s2013 nju ob 001 0 eng 2012040270 9781118354582 (epub) 1118354583 (epub) 9781118354575 (pdf) 1118354575 (pdf) 9781118354568 (mobi) 1118354567 (mobi) 9781118354599 (electronic bk.) 1118354591 (electronic bk.) 9781299241954 (MyiLibrary) 1299241956 (MyiLibrary) 9780470646274 (cloth) 0470646276 (cloth) AU@ 000050086446 CHBIS 009914530 CHVBK 175204659 DKDLA 820120-katalog:000655910 NLGGC 356864928 NZ1 15340367 NZ1 15905471 DEBBG BV043395079 (OCoLC)811850420 (OCoLC)828793860 (OCoLC)961568624 (OCoLC)962707379 (OCoLC)966257693 DLC eng pn DLC YDX DG1 N$T YDXCP E7B CDX IDEBK COO NOC OCLCF CCO NLGGC RECBK EBLCP OCLCQ OCLCO D6H LOA pcc MAIN RM301.4 .F87 2013 QU 450 MED 071000 bisacsh 615.7 23 Fusion protein technologies for biopharmaceuticals : applications and challenges / edited by Stefan R. Schmidt. [electronic resource] Hoboken, New Jersey : John Wiley & Sons, ©2013. 1 online resource. text txt rdacontent computer c rdamedia online resource cr rdacarrier Includes bibliographical references and index. pt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm. The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei. Print version record and CIP data provided by publisher. Biopharmaceutics. Pharmaceutical biotechnology. Drug carriers. Immunotoxins Therapeutic use. Protein engineering. Recombinant fusion proteins Therapeutic use. MEDICAL Pharmacology. bisacsh Biopharmaceutics. fast (OCoLC)fst00832650 Pharmaceutical biotechnology. fast (OCoLC)fst01060106 Recombinant Fusion Proteins therapeutic use. Drug Carriers. Immunotoxins pharmacokinetics. Immunotoxins therapeutic use. Protein Engineering. Recombinant Fusion Proteins pharmacokinetics. Electronic books. Electronic books. local Schmidt, Stefan R. Print version: Fusion protein technologies for biopharmaceuticals. Hoboken, N.J. : John Wiley & Sons, ©2013 9780470646274 (DLC) 2012039440 http://onlinelibrary.wiley.com/book/10.1002/9781118354599 Wiley Online Library ddc BK 206191 206191